IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS SUBSIDIARY LISTING
tion). Es tab lished 1927. 220 phar ma ceu ti cal
employees in 2005.
Rep re sen ta tives/De tail ers (Pharm, Num -
ber): 1-10 (2005)
Con tacts (Pharm): Chair man: Karsten H.
Skaffe, Jeanette Stids-Jonsby; Com mer cial Op er -
a tions: Birgit Larsen; Gen eral Con tact: Jeanette
Stids-Jonsby
Phar ma ceu ti cal Sales: US$ 22-24 mil lion
Prod ucts (% of Sales by Lead ing 5): 60-65%
Ther a peu tic Classes (% of Sales by Lead ing
5): 75-80%
Dose Forms (% of Sales by Lead ing 5): n.a.
Prin ci pal Prod ucts:
METOPROLOLSUCC HEX (beta-blocker agent
plain)
CORODIL (ACE in hib i tor plain)
SIMVASTATIN HEXAL (cho les terol/triglyceride
reg u lat ing prep a ra tion)
AMLODIPIN HEXAL (cal cium an tag o nist plain)
ORABET (antidiabetic oral)
Ther a peu tic Range:
beta-block ing agents 40%
renin-an gio ten sin sys tem agents 19%
lipid-reg u lat ing/antiatheroma prep a ra tions 9%
cal cium an tag o nists 5%
psychoanaleptics 5%
Lead ing Dose Forms:
tab lets 76%
coated tab lets 21%
cap sules 3%
am poules -
NOVARTIS
Full Name: Novartis Healthcare A/S
Street Ad dress: Lyngbyvej 172, DK-2100
Kobenhavn
Tel: +45 39 16 84 00
Fax: +45 39 16 84 01
Email: skriv.til@novartis.com
Home Page: www.novartis.dk
De scrip tion: Re searcher, im porter, pro moter,
sales/detailer. Prod uct ranges in clude: phar ma -
ceu ti cal prod ucts (branded, unbranded, pre scrip -
tion, non-pre scrip tion), hos pi tal pharmaceuticals,
di etetic/nu tri tional prod ucts, oph thal mic prod -
ucts, vet er i nary pharmaceuticals. Es tab lished
1997. 148 phar ma ceu ti cal em ploy ees in 2007. Di -
vi sions in clude: Novartis Pharmaceuticals.
Pharma; Con sumer Health; An i mal Health;
Sandoz; Medical Nutrition.
Rep re sen ta tives/De tail ers (Pharm, Num -
ber): 21-50 (2007)
Con tacts (Pharm): Chair man: Ja son Smith;
Com mer cial Op er a tions: Ja son Smith; Mar ket Re -
search: Thomas Klaening; Re search & De vel op -
ment: Jan Narvestad; Gen eral Con tact: Thomas
Klaening
Sub sid iary of: Novartis, Swit zer land (100%)
Phar ma ceu ti cal Sales: US$ 100-110 mil lion
Prod ucts (% of Sales by Lead ing 5): 40-45%
Ther a peu tic Classes (% of Sales by Lead ing
5): 55-60%
Dose Forms (% of Sales by Lead ing 5):
75-80%
Prin ci pal Prod ucts:
GLIVEC (antineoplastic other)
NICOTINELL MINT (antismoking prod uct)
RITALIN UNO (psychostimulant)
SANDOSTATIN LAR (hor mone hy po tha lamic)
ZOMETA (bone cal cium reg u la tor)
Ther a peu tic Range:
CNS drugs other 20%
antineoplastics 15%
renin-an gio ten sin sys tem agents 9%
psychoanaleptics 8%
immunosuppressive agents 7%
Lead ing Dose Forms:
coated tab lets 31%
spe cial solid forms 16%
cap sules 14%
liq uids 10%
in fu sions 7%
SANDOZ
Full Name: Sandoz A/S
Street Ad dress: C. F. Tietgens Bou le vard 40,
DK-5220 Odense S
Tel: +45 63 95 10 00
Fax: +45 63 95 10 01
Email: info.sandoz-dk@sandoz.com
Home Page: www.sandoz.dk
De scrip tion: De vel oper, man u fac turer,
packager/as sem bler, im porter, ex porter, dis trib -
u tor, pro moter, sales/detailer. Prod uct ranges in -
clude: phar ma ceu ti cal prod ucts (branded,
pre scrip tion, non-pre scrip tion), hos pi tal
pharmaceuticals, bi o log i cal prod ucts. Es tab lished
1982. 120 pharmaceutical employees in 2008.
Rep re sen ta tives/De tail ers (Pharm, Num -
ber): 8 (2008)
Con tacts (Pharm): Chair man: Olof Milveden;
Com mer cial Op er a tions: Erik Furstrung; Man u -
© 2009 IMS Health In cor po rated or its af fil i ates Page 162